US 12,110,338 B2
Site-specific antibody-drug conjugation through glycoengineering
Clark Pan, Sutton, MA (US); Qun Zhou, Ashland, MA (US); James Stefano, Hopkinton, MA (US); Pradeep Dhal, Westford, MA (US); Bo Chen, Boston, MA (US); Diego Gianolio, Somerville, MA (US); Robert Miller, East Bridgewater, MA (US); and Huawei Qiu, Westborough, MA (US)
Assigned to Genzyme Corporation, Cambridge, MA (US)
Filed by Genzyme Corporation, Cambridge, MA (US)
Filed on Aug. 17, 2021, as Appl. No. 17/404,412.
Application 17/404,412 is a division of application No. 16/238,932, filed on Jan. 3, 2019, granted, now 11,130,816.
Application 15/417,648 is a division of application No. 14/203,479, filed on Mar. 10, 2014, granted, now 9,580,511, issued on Feb. 28, 2017.
Application 16/238,932 is a continuation of application No. 15/417,648, filed on Jan. 27, 2017, granted, now 10,214,589, issued on Feb. 26, 2019.
Claims priority of provisional application 61/776,710, filed on Mar. 11, 2013.
Claims priority of provisional application 61/776,724, filed on Mar. 11, 2013.
Claims priority of provisional application 61/776,715, filed on Mar. 11, 2013.
Prior Publication US 2022/0089763 A1, Mar. 24, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 47/54 (2017.01); A61K 47/68 (2017.01); C07K 16/32 (2006.01); C07K 16/40 (2006.01)
CPC C07K 16/2893 (2013.01) [A61K 47/549 (2017.08); A61K 47/6803 (2017.08); A61K 47/6869 (2017.08); A61K 47/6889 (2017.08); C07K 16/28 (2013.01); C07K 16/2809 (2013.01); C07K 16/2851 (2013.01); C07K 16/32 (2013.01); C07K 16/40 (2013.01); C07K 2317/40 (2013.01); C07K 2317/41 (2013.01); C07K 2317/522 (2013.01); C07K 2317/56 (2013.01); C07K 2317/71 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/00 (2013.01)] 29 Claims
 
1. A method of treating a HER2+ cancer in a subject, the method comprising administering to the subject an effective amount of a binding polypeptide comprising:
at least one modified glycan comprising at least one moiety of Formula (IV):
-Gal-Sia-C(H)=N-Q-CON-X   Formula (IV),
wherein:
A) Q is NH or O;
B) CON is a connector moiety;
C) X is a therapeutic effector moiety;
D) Gal is a galactose moiety; and
E) Sia is a sialic acid moiety
wherein the subject has a HER2+ tumor, and
wherein the binding polypeptide is an anti-HER2 antibody.